Recent Analysts’ Ratings Changes for Denali Therapeutics (DNLI)

Denali Therapeutics (NASDAQ: DNLI) has recently received a number of price target changes and ratings updates:

• 3/10/2025 – Denali Therapeutics had its price target lowered by analysts at Bank of America Co. from $30.00 to $28.00. They now have a “buy” rating on the stock.
• 3/7/2025 – Denali Therapeutics is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $33.00 price target on the stock.
• 3/5/2025 – Denali Therapeutics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $35.00 price target on the stock, down previously from $38.00.
• 3/3/2025 – Denali Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $42.00. They now have an “outperform” rating on the stock.
• 2/28/2025 – Denali Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 2/28/2025 – Denali Therapeutics had its price target raised by analysts at HC Wainwright from $80.00 to $87.00. They now have a “buy” rating on the stock.
• 2/11/2025 – Denali Therapeutics is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $31.00 price target on the stock.
• 1/28/2025 – Denali Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $45.00 to $40.00. They now have a “buy” rating on the stock.

Denali Therapeutics Stock Down 5.4 %

Shares of DNLI traded down $0.83 during trading on Tuesday, reaching $14.61. 368,521 shares of the company traded hands, compared to its average volume of 1,000,180. The stock has a 50-day simple moving average of $20.17 and a 200-day simple moving average of $23.90. Denali Therapeutics Inc. has a twelve month low of $14.01 and a twelve month high of $33.33. The stock has a market cap of $2.12 billion, a PE ratio of -5.29 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, equities research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, insider Carole Ho sold 12,255 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. This trade represents a 6.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 over the last ninety days. Insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock worth $244,993,000 after purchasing an additional 843,996 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after acquiring an additional 903,683 shares in the last quarter. FMR LLC raised its stake in Denali Therapeutics by 2.4% in the 4th quarter. FMR LLC now owns 8,019,746 shares of the company’s stock valued at $163,442,000 after purchasing an additional 188,368 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in Denali Therapeutics by 8.8% during the 4th quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company’s stock worth $67,573,000 after acquiring an additional 268,378 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.